[go: up one dir, main page]

WO1992021333A3 - Traitement des symptomes de sevrage et de manque dus a des drogues au moyen d'inhibiteurs d'oxydase de monoamine de type b - Google Patents

Traitement des symptomes de sevrage et de manque dus a des drogues au moyen d'inhibiteurs d'oxydase de monoamine de type b Download PDF

Info

Publication number
WO1992021333A3
WO1992021333A3 PCT/US1992/003702 US9203702W WO9221333A3 WO 1992021333 A3 WO1992021333 A3 WO 1992021333A3 US 9203702 W US9203702 W US 9203702W WO 9221333 A3 WO9221333 A3 WO 9221333A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
monoamine oxidase
withdrawal symptoms
type
craving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1992/003702
Other languages
English (en)
Other versions
WO1992021333A2 (fr
Inventor
George W Belendiuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supernus Pharmaceuticals Inc
Original Assignee
Pharmavene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmavene Inc filed Critical Pharmavene Inc
Publication of WO1992021333A2 publication Critical patent/WO1992021333A2/fr
Publication of WO1992021333A3 publication Critical patent/WO1992021333A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Procédés de traitement des symptômes de sevrage et de prévention ou de diminution du manque de psychostimulants créant une accoutumance (par exemple, la cocaïne), des opiacés, de l'alcool ou de la nicotine, au moyen de l'administration à un patient d'un inhibiteur d'oxydase de monoamine de type B, en quantité efficace pour atténuer les symptômes de sevrage et supprimer ou diminuer le manque de psychostimulants créant une accoutumance, d'opiacés, d'alcool ou de nicotine. Un inhibiteur d'oxydase de monoamine de type B est le L-deprenyl ou la sélégiline.
PCT/US1992/003702 1991-05-24 1992-05-04 Traitement des symptomes de sevrage et de manque dus a des drogues au moyen d'inhibiteurs d'oxydase de monoamine de type b Ceased WO1992021333A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70508591A 1991-05-24 1991-05-24
US705,085 1991-05-24

Publications (2)

Publication Number Publication Date
WO1992021333A2 WO1992021333A2 (fr) 1992-12-10
WO1992021333A3 true WO1992021333A3 (fr) 1993-01-07

Family

ID=24831978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/003702 Ceased WO1992021333A2 (fr) 1991-05-24 1992-05-04 Traitement des symptomes de sevrage et de manque dus a des drogues au moyen d'inhibiteurs d'oxydase de monoamine de type b

Country Status (2)

Country Link
AU (1) AU1992592A (fr)
WO (1) WO1992021333A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9974752B2 (en) 2014-10-31 2018-05-22 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713087B1 (fr) * 1993-11-30 1996-02-23 Saurat Jean Hilaire Utilisation de la sélégiline et ses dérivés pour la préparation d'un médicament destiné au traitement du psoriasis.
DE4428444A1 (de) * 1994-08-11 1996-02-15 Dresden Arzneimittel Verwendung von Selegilin zur Behandlung von epileptischen Erkrankungen
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
JPH10513455A (ja) * 1995-02-10 1998-12-22 ザ ユニバーシティ オブ トロント イノベーションズ ファウンデーション 緑内障治療用のデプレニル化合物
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
NZ309980A (en) 1995-06-07 2001-06-29 Noven Pharma Transdermal composition containing a blend of one or more polymers, one or more drugs that has a low molecular weight and is liquid at room temperature
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
US6210705B1 (en) * 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
PT1441708E (pt) 2001-11-05 2009-06-18 Krele Pharmaceuticals Llc Composições e métodos para aumentar a observância de terapias utilizando inibidores da aldeído desidrogenase e para tratar alcoolismo
WO2004009116A2 (fr) 2002-07-18 2004-01-29 Cytos Biotechnology Ag Conjugues haptene-porteur et utilisations de ceux-ci
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
EP1686973A4 (fr) 2003-11-25 2009-03-25 Technion Res & Dev Foundation Compositions et procedes pour traiter des troubles et des maladies cardiovasculaires
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
DE102006038719A1 (de) 2006-08-18 2008-02-21 Tesa Ag Haftklebestreifen für feuchtigkeitsunempfindliche wiederablösbare Verklebungen
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2475428B1 (fr) 2009-09-11 2015-07-01 Probiodrug AG Dérivés hétérocycliques en tant qu'inhibiteurs de glutaminyle cyclase
MX354423B (es) 2010-02-03 2018-03-02 Pharma Two B Ltd Star Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
EA022420B1 (ru) 2010-03-10 2015-12-30 Пробиодруг Аг Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5)
WO2011131748A2 (fr) 2010-04-21 2011-10-27 Probiodrug Ag Nouveaux inhibiteurs
US20130165511A1 (en) * 2010-09-01 2013-06-27 TONIX Pharmaceuticals Holding Corp Treatment for cocaine addiction
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
US9937144B2 (en) 2013-01-30 2018-04-10 The Johns Hopkins University Treatment of drug abuse by preventing GAPDH nitrosylation
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEMENTIA, Vol. 1 (6), 1990, KABINS, DARRYL AND SAMUEL GERSHON, "Potential Applications for Monoamine Oxidase B Inhibitors, pp. 323-348. *
MED. CLIN. N. AM., Vol. 72(4), 1988, KRANZLER, H.R. AND N.R. LIEBOWITZ, "Anxiety and Depression in Substance Abuse", pp. 867-885. *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10507186B2 (en) 2014-10-31 2019-12-17 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10111839B2 (en) 2014-10-31 2018-10-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10292939B2 (en) 2014-10-31 2019-05-21 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10292938B2 (en) 2014-10-31 2019-05-21 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10449159B2 (en) 2014-10-31 2019-10-22 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10500162B2 (en) 2014-10-31 2019-12-10 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US9974752B2 (en) 2014-10-31 2018-05-22 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10512612B2 (en) 2014-10-31 2019-12-24 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10512613B2 (en) 2014-10-31 2019-12-24 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10568841B2 (en) 2014-10-31 2020-02-25 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10688060B2 (en) 2014-10-31 2020-06-23 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11896722B2 (en) 2014-10-31 2024-02-13 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Also Published As

Publication number Publication date
AU1992592A (en) 1993-01-08
WO1992021333A2 (fr) 1992-12-10

Similar Documents

Publication Publication Date Title
WO1992021333A3 (fr) Traitement des symptomes de sevrage et de manque dus a des drogues au moyen d'inhibiteurs d'oxydase de monoamine de type b
CA2181048A1 (fr) Methode assurant une anesthesie corneenne prolongee et etendue
EP1555025A3 (fr) Utilisation d'analogues de déhydroépiandrostérone pour le traitement de l'asthme
GB9106678D0 (en) Wound healing
NO923859L (no) Medikament
LU92615I2 (fr) Alogliptin et ses dérivés pharmaceutiquement acceptables (VIPIDIA)
CA2129541A1 (fr) Methode pour favoriser la retention d'azote chez les humains
GR3030041T3 (en) Prolonged activity nicotine patch
CA2245661A1 (fr) Traitement de la sclerose en plaques
MY106528A (en) Method of treating impotence.
CA2251966A1 (fr) Administration transdermique de dextromethorphane servant d'agent antitussif
ES2166001T3 (es) Utilizacion de compuestos antimineralcorticoides contra el sindrome de abstinencia de narcoticos.
DE69326459D1 (de) Wirkstoffe zur behandlung von suchterkrankungen
PT659082E (pt) Utilizacao de inibidores de citocromo p450 para inibir o metabolismo de acridina substituida com azoto
JPS6483020A (en) Medicinal composition for preventing or treating aids
Suedfeld et al. Restricted environmental stimulation therapy of smoking: A parametric study
IE881115L (en) Inhibitors of angiogenin
ZA953500B (en) Methods for treating neurofibromatosis
NO950599L (no) Fremgangsmåte for inhibering av HIV-replikasjon ved anvendelse av IL-4
WO1997026880A3 (fr) Utilisation d'une combinaison de delavirdine et d'un ou plusieurs inhibiteurs de protease chez des patients contamines par le vih-1
Kontoes A study of the effect of morphine and methadone on the enzymic system of the protozoan Tetrahymena pyriformis. A possible explanation of the abstinence syndrome induced by opiates.
Borg et al. Cocaine abuse is decreased with effective methadone maintenance treatment at an urban Department of Veterans Affairs (DVA) Program
Borg et al. Cocaine abuse is decreased with effective methadone maintenance treatment at an urban Department of Veterans Affairs (DVA) Program
Pycha et al. Buprenorphine: Rapid and slow dose-reductions for heroin detoxification
RU95102652A (ru) Средство и способ коррекции и профилактики патологического симптомокомплекса при внутренних болезнях и заболеваниях нервной системы

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase